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INTRODUCTION AND OBJECTIVES_________________________________________________________________  
• Chronic hepatitis C (CHC) is usually associated with iron overload, which may modulate the severity of liver disease.
• Direct-acting antivirals (DAAs) have made CHC treatment faster and more efficient. However, little is known about their effect on liver disease severity and iron
metabolism disruption.
• This study aimed to evaluate the role of iron related gene variants in liver disease severity and iron status associated parameters in CHC patients treated with DAAs.
MATERIALS AND METHODS______________________________________________________________________ 
RESULTS______________________________________________________________________________________
• Patients with higher fibrosis grade (F3/4) had: 
Increased levels of serum iron (p=0.030), total iron-
binding capacity (p=0.025) and ferritin (p=0.026),
and decreased haptoglobin (p=0.048).
• Patients with HFE_CY or HFE_YY presented:
Increased level of serum iron (p=0.008),
transferrin saturation (p=0.003) and
ferritin (p=0.002).
• Patients with TF_rs3811647_GA or _AA 
presented: 
Increased total iron-binding capacity (p=0.029).
• Increased frequency of patients with lower fibrosis grade (F1/2) (p <0.001).
POST-THERAPEUTIC
PRE-THERAPEUTIC
• Decreased serum iron (p = 0.007), transferrin saturation (p <0.001)
and ferritin (p = 0.007), and increased haptoglobin (p = 0.001).
• Only patients HFE_CC and HFE_HD or HFE_DD had: decreased total iron-binding capacity (p = 0.006) and increased haptoglobin (p = 0.013).
• Only patients TF_rs3811647_GG or _GA presented: increased haptoglobin (p = 0.006).
CONCLUSION_________________________________________________________________________________
 Specific genetic variants in iron related genes may have a relevant role in the predisposition for
severe liver disease in CHC patients before DAAs treatment, and in the improvement of iron
status after HCV clearance.
Before DAA treatment, genetic polymorphisms 
HFE_H63D and TF_rs3811647 may indirectly 
influence the severity of liver disease 
through iron-related metabolic parameters.
After DAA treatment, genetic polymorphisms 
HFE_H63D, HFE_C282Y and TF_rs3811647 
influence iron-related metabolic changes 
induced by elimination of HCV.
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